A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Trial Details

NCT ID
NCT07439653
Phase
PHASE1 / PHASE2
Sponsor
TORL Biotherapeutics, LLC
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • TORL-5-700
  • TORL-5-700 at MTD/RP2D
  • TORL-5-700 at MTD/RP2D in combination with another agent
Locations (sample)
  • Fullerton, California, United States|33.87029,-117.92534
  • Santa Monica, California, United States|34.01949,-118.49138
  • Stanford, California, United States|37.42411,-122.16608
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
  • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
  • At least 1 measurable lesion per Lugano criteria.
  • Tumor tissue is available.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →